Aequus Pharmaceuticals Inc. (TSXV:AQS)

Market Cap	663.17K -66.7%
Revenue (ttm)	918.47K +122.3%
Net Income	-656.34K
EPS	-0.00
Shares Out	132.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100,000
Open	0.0050
Previous Close	0.0050
Day's Range	0.0050 - 0.0050
52-Week Range	0.0050 - 0.0400
Beta	-0.21
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Aequus Pharmaceuticals

Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 12
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: AQS

Financial Performance

In 2024, Aequus Pharmaceuticals's revenue was 584,237, an increase of 129.21% compared to the previous year's 254,896. Losses were -2.18 million, -26.55% less than in 2023.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 26, 2026

Data Sources Report a data error